Harrison, Simon J.

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 827

Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition

Hogg, S. J., Motorna, O., Cluse, L. A., Johanson, T. M., Coughlan, H. D., Raviram, R., Myers, R. M., Costacurta, M., Todorovski, I., Pijpers, L., et al. (2021) · Molecular Cell

Genomics and Chromatin DynamicsEpigenetics and DNA Methylation

Cited by 170

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

Trudel, S., Cohen, A. D., Krishnan, A. Y., Fonseca, R., Spencer, A., Berdeja, J. G., Lesokhin, A., Forsberg, P. A., Laubach, J. P., Costa, L. J., et al. (2021) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 165

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Spencer, A., Yoon, S.-S., Harrison, S. J., Morris, S. R., Smith, D. A., Brigandi, R. A., Gauvin, J., Kumar, R., Opalinska, J. B., & Chen, C. (2014) · Blood

Multiple Myeloma Research and TreatmentsPI3K/AKT/mTOR signaling in cancer

Cited by 142

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

Ling, S. C. W., Lau, E. K. K., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, P. J., Harrison, S., Fleming, S., et al. (2012) · Haematologica

Multiple Myeloma Research and TreatmentsEndoplasmic Reticulum Stress and Disease

Cited by 130

Oseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, Australia

Tramontana, A. R., George, B., Hurt, A. C., Doyle, J. S., Langan, K., Reid, A. B., Harper, J. M., Thursky, K., Worth, L. J., Dwyer, D. E., et al. (2010) · Emerging Infectious Diseases

Influenza Virus Research StudiesRespiratory viral infections research

Cited by 127

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Harrison, S. J., Minnema, M. C., Lee, H. C., Spencer, A., Kapoor, P., Madduri, D., Larsen, J., Ailawadhi, S., Kaufman, J. L., Raab, M. S., et al. (2020) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 112

Infectious complications of bispecific antibody therapy in patients with multiple myeloma

Sim, B. Z., Longhitano, A., Er, J., Harrison, S. J., Slavin, M. A., & Teh, B. W. (2023) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 50